The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Confirm
Session Speakers:
Adapting CMC Bioassay Strategies in Response to an Evolving ADC Pipeline
Patrick Hussman, AstraZeneca
Co-validation and Technology Transfer of an Automated Cell-Based Potency Method
Shelley Fang, GlaxoSmithKline
Apples and Oranges - Case Studies on Similarity, Comparability and Equivalence Regarding Potency Determination
Hermann Beck, F. Hoffmann-La Roche Ltd.
Regulatory Considerations for Bioassay Lifecycle Management
Leiyun Boone, CDER, FDA